- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03502434
Een Repeat Insult Patch Test (RIPT)-onderzoek ter evaluatie van het sensibiliseringspotentieel van lokale SM04755-oplossing bij gezonde vrijwilligers
Een fase 1, Single-Center, Repeat Insult Patch Test (RIPT)-onderzoek ter evaluatie van het sensibiliseringspotentieel van lokale SM04755-oplossing
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This Phase 1, Repeat Insult Patch Test (RIPT) study is a single-center study of topical SM04755 solution repetitively applied to skin of healthy volunteers. This study will assess the potential of the Test Materials to induce contact sensitization as measured by treatment emergent adverse events (TEAEs), Reaction Grade and Investigator assessment of irritation and sensitization.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Virginia
-
Lynchburg, Virginia, Verenigde Staten, 24503
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy adult males and females at least 18 years of age
- Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator or designee's opinion, interfere with study assessments
- Subject has no signs of irritation (i.e., a Reaction Grade of "0") at patch application sites on the back prior to the initial patch application on Day 1
- Subject must have read, understood, and signed the informed consent form prior to any study-related procedure being performed
- Subject is willing and able to comply with all scheduled study visits, urine pregnancy tests (if applicable), contraception requirements (male and female), and other study requirements
- Subject is willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study
Exclusion Criteria:
- Women who are pregnant or lactating
- Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period that includes double barrier, IUD, or hormonal contraceptive combined with single barrier, or abstinence
- Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to Day 1
- Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD, or hormonal contraception combined with single barrier)
- Subject has any skin condition that, in the Investigator's opinion, could interfere with the study assessments or put the subject at undue risk by study participation
- Subject has severe atopic dermatitis/eczema, psoriasis or chronic asthma
- Subject has tattoos, excessive hair, moles, scarring, etc. which would interfere with patching
- Subject has a history of sensitivity to any component of any of the Test Materials
- Use of any of the following medications:
- Systemic or topical glucocorticoids within 4 weeks prior to Day 1
- Systemic or topical analgesics (e.g., NSAIDs, high dose aspirin, etc.) within 1 week prior to Day 1. Note: Daily use of ≤325 mg of aspirin for cardiovascular disease or prophylaxis is allowed. Maximum daily use of Tylenol ≤3000 mg is allowed.
- Antihistamines within 1 week prior to Day 1. Note: H2 blockers such as Pepcid, Zantac, and Tagamet are permitted.
- Anti-inflammatories within 1 week prior to Day 1
- Immunosuppressant medications (e.g., TNF-alpha inhibitors, topical tacrolimus, etc.) within 4 weeks prior to Day 1 (or within 6 half-lives prior to Day 1 for biologics)
- Subject has had previous treatment with SM04755
- Subject has an active infection of hepatitis B or C or human immunodeficiency virus (HIV) infection as determined by an interview
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 8 weeks prior to Screening, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to Screening
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 90 mg/mL SM04755 in water
90 mg/mL SM04755 in water applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimenteel: 90 mg/mL SM04755 in aqueous Vehicle
90 mg/mL SM04755 in aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimenteel: 90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)
90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Ander: Vehicle
Aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Ander: White petrolatum
White petrolatum (Negative control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Ander: Sodium lauryl sulfate
Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Contactsensibiliseringspotentieel van testmateriaal zoals gemeten door Treatment emergent
Tijdsspanne: Basislijn tot dag 40 (of gedurende de observatieperiode voor TEAE's)
|
Basislijn tot dag 40 (of gedurende de observatieperiode voor TEAE's)
|
|
|
Contactsensibiliseringspotentieel van testmateriaal zoals gemeten door onderzoekerbeoordeling van irritatie en sensibilisatie
Tijdsspanne: Basislijn tot dag 40
|
Basislijn tot dag 40
|
|
|
Contact sensitization potential of Test Material as measured by Reaction Grade
Tijdsspanne: Baseline to Day 38-40
|
Reaction Grade is measured on a 5-point scale from zero to four (zero = no sign of irritation and 4 = Erythema with edema and blistering) |
Baseline to Day 38-40
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SM04755-TOP-02
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .